Fiasp

Active substance: insulin aspart

INJECTION, SOLUTION · INSULIN ASPART 100 [iU]/mL

United StatesActive

Marketing holder: Novo Nordisk

Verified 2026-10-09 · openFDA NDC

Composition

Analogues by country

Products with the same active substance registered in other countries.

Country	Products
EU 9	Dazparda insulin aspart EMEA/H/C/006187 Gan & Lee Pharmaceuticals Europe GmbH Fiasp insulin aspart EMEA/H/C/004046 Novo Nordisk A/S Insulin Aspart Injection insulin aspart EMEA/H/C/006720 Masuu Pharma Europe Limited Insulin aspart Sanofi insulin aspart EMEA/H/C/005033 Sanofi Winthrop Industrie Kirsty (previously Kixelle) insulin aspart EMEA/H/C/004965 Biosimilar Collaborations Ireland Limited All products in this country (9)

Country

Products

EU 9

Dazparda
insulin aspart
EMEA/H/C/006187
Gan & Lee Pharmaceuticals Europe GmbH
Fiasp
insulin aspart
EMEA/H/C/004046
Novo Nordisk A/S
Insulin Aspart Injection
insulin aspart
EMEA/H/C/006720
Masuu Pharma Europe Limited
Insulin aspart Sanofi
insulin aspart
EMEA/H/C/005033
Sanofi Winthrop Industrie
Kirsty (previously Kixelle)
insulin aspart
EMEA/H/C/004965
Biosimilar Collaborations Ireland Limited

Registration

Sources

product · openFDA NDC · 0169-3205 · Verified 2026-10-09 · open in source
registration_status · openFDA NDC · 0169-3205 · Verified 2026-10-09 · open in source
ingredients.0 · openFDA NDC · 0169-3205 · Verified 2026-10-09 · open in source